Interleukin-21 mediates hepatitis B virus-associated liver cirrhosis by activating hepatic stellate cells

Hepatology Research

Volumn 44, Issue 10, 2014, Pages E198-E205

  Feng, Guohua ^a   Zhang, Ji Yuan ^b   Zeng, Qing Lei ^a   Yu, Xi ^a   Zhang, Zheng ^b   Lv, Sa ^b   Xu, Xiangsheng ^b   Wang, Fu Sheng ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING 302 HOSPITAL   (China)

Author keywords

Hepatic stellate cell; Hepatitis B virus associated liver cirrhosis; Interleukin 21

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; INTERLEUKIN 21;

ADULT; APOPTOSIS; ARTICLE; BIOACCUMULATION; CD4+ T LYMPHOCYTE; CELL COUNTING; CELL PROLIFERATION; CHEMOLUMINESCENCE; CHILD PUGH SCORE; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROGENESIS; FLOW CYTOMETRY; HEPATIC STELLATE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CIRRHOSIS; MALE; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

EID: 84907877673     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12215     Document Type: Article

References (28)

1. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229.
2. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008; 12: 733-746.
3. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456.
4. Wang FS. Clinical immune characterization of hepatitis B virus infection and implications for immune intervention: progress and challenges. Hepatol Res 2007; 37 (Suppl 3): S339-346.
5. Wang FS, Zhang Z. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol 2009; 3: 499-512.
6. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.
7. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172.
8. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
9. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008; 26: 57-79.
10. Parrish-Novak J, Dillon SR, Nelson A etal. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000; 408: 57-63.
11. Publicover J, Goodsell A, Nishimura S etal. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 2011; 121: 1154-1162.
12. Ma SW, Huang X, Li YY etal. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol 2012; 56: 775-781.
13. Hsu CS, Hsu SJ, Liu WL etal. IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients. Antivir Ther 2013. doi:10.3851/IMP2502.
14. Pesce J, Kaviratne M, Ramalingam TR etal. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 2006; 116: 2044-2055.
15. Hesse M, Modolell M, La Flamme AC etal. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol 2001; 167: 6533-6544.
16. Duffield JS, Forbes SJ, Constandinou CM etal. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65.
17. Mookerjee RP, Stadlbauer V, Lidder S etal. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007; 46: 831-840.
18. Tritto G, Bechlis Z, Stadlbauer V etal. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. J Hepatol 2011; 55: 574-581.
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
20. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
21. Sun HQ, Zhang JY, Zhang H, Zou ZS, Wang FS, Jia JH. Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. J Viral Hepat 2012; 19: 396-403.
22. Kong X, Feng D, Wang H etal. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012; 56: 1150-1159.
23. Zhang Z, Zou ZS, Fu JL etal. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J Hepatol 2008; 49: 396-406.
24. Iannello A, Boulassel MR, Samarani S etal. Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J Immunol 2010; 184: 114-126.
25. Hu X, Ma S, Huang X etal. Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J Viral Hepat 2011; 18: 458-467.
26. Li Y, Ma S, Tang L etal. Circulating CXCR5+ CD4+ T cells benefit hbeag seroconversion through IL-21 in patients with chronic HBV infection. Hepatology 2013. doi:10.1002/hep.26489.
27. Xu L, Hui AY, Albanis E etal. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005; 54: 142-151.
28. Monteleone G, Pallone F, MacDonald TT. Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol 2008; 29: 290-294.